Russell Bradley Home Ron Andrews KOL Symposium at SNO/ASCO CNS Metastases 2025 Theranostics earmarked as “the future” of radiopharmaceuticals Progress, Potential, and Possibilities Show Stocktwits Interview with Plus Therapeutics CEO Game on Glio Podcast with Dr. Toral Patel and Dr. Andrew Brenner Q&A: Metastatic cancer assay for ‘getting people answers’ Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers Houston Business Journal pharmaphorum podcast: On Targeted Radiotherapeutics Contact What emerging technologies or scientific breakthroughs do you believe will most reshape biopharma in the next 10 years? Forward Looking Statement Russ Havranek Daniel Ortega Marc Hedrick Can Radiotherapeutics and Early Detection Offer a Breakthrough for Rare CNS Cancer? Radiopharma pipeline builds ahead of key data CNSide® at BioHouston LiveLung Leptomeningeal Metastases Webinar AI-Powered Diagnostics and Targeted Radiotherapy for CNS Cancers with Dr. Marc Hedrick Plus Therapeutics JPM 2026: what’s the outlook like this year? REYOBIQ™ (rhenium Re186 obisbemeda) Partnership Opportunities Recurrent Glioblastoma Careers Our Team KSAT News: ReSPECT-GBM at the Mays Cancer Center Using Targeted Radiotherapies to Treat Challenging CNS Cancers What role is precision medicine playing in transforming cancer treatment — and how are developers adapting? Central nervous system cancer metastases – the evolution of diagnostics and treatment Phase 1 RNL-186 Shows Promise in Leptomeningeal Metastases: Andrew Brenner, MD, PhD Breaking barriers in leptomeningeal metastases diagnosis with CNSide Diagnostics Adding Up: Plus Therapeutics Gets First Metastatic CNS Cancer Assay Insured Medical Device Network Interview with CNSide® President For Patients About Us Pediatric Brain Cancer Leptomeningeal Metastases Fox SA Interview with Andrew Brenner, MD, PhD Cancer Network Interviews with Andrew Brenner, MD, PhD Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers “The Power of Plus Therapeutics” with Game on Glio Targeting CNS Cancers with Precision Radiotherapeutics Plus Therapeutics CEO Interview with Alpha Street “Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma” Houston cancer diagnostics company enters new phase with patient testing CLIA Accreditation Clears Path for CNSide Diagnostics’ CSF Assay Platform